Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported Q4 EPS of ($1.34), versus ($1.60) reported last year. Revenue for the quarter came in at $158.33 thousand versus the consensus estimate of $382 thousand.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals (ARWR) click here.